ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy

Clinical Neurophysiology

Volumn 119, Issue 3, 2008, Pages 533-541

  Kreukels, Baudewijntje P C ^a   Hamburger, Hans L ^b   de Ruiter, Michiel B ^a   van Dam, Frits S A M ^a,c   Ridderinkhof, K Richard ^c,d   Boogerd, Willem ^a,b   Schagen, Sanne B ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Adjuvant chemotherapy; Breast cancer; Cognitive deficits; Event related potentials; Long term side effects; Neurotoxicity

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; THIOTEPA;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER SURVIVOR; CONTROLLED STUDY; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; ELECTROPHYSIOLOGY; EVENT RELATED POTENTIAL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ACOUSTIC STIMULATION; ADULT; ANALYSIS OF VARIANCE; BRAIN MAPPING; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CROSS-OVER STUDIES; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; REACTION TIME; SURVIVORS;

EID: 39049164270     PISSN: 13882457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinph.2007.11.011     Document Type: Article

References (38)

1. Ahles T.A., and Saykin A.J. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7 (2007) 192-201
2. Ahles T.A., Saykin A.J., Furstenberg C.T., Cole B., Mott L.A., Skalla K., et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20 (2002) 485-493
3. Barry R.J., Johnstone S.J., and Clarke A.R. A review of electrophysiology in attention-deficit/hyperactivity disorder: II. Event-related potentials. Clin Neurophysiol 114 (2003) 184-198
4. Bleyer W.A. Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 65 Suppl. 1 (1981) 89-98
5. Boogerd W. Neurological complications of chemotherapy. In: Vinken P.J., and Bruyn G.W. (Eds). Handbook of clinical neurology: intoxications of the nervous system part II (1995), Elsevier Science 527-546
6. Brezden C.B., Phillips K.A., Abdolell M., Bunston T., and Tannock I.F. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18 (2000) 2695-2701
7. Castellon S.A., Ganz P.A., Bower J.E., Petersen L., Abraham L., and Greendale G.A. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26 (2004) 955-969
8. Falleti M.G., Sanfilippo A., Maruff P., Weih L., and Phillips K.A. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 59 (2005) 60-70
9. Ferguson R.J., McDonald B.C., Saykin A.J., and Ahles T.A. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol 25 (2007) 3866-3870
10. Halliday R., Naylor H., Brandeis D., Callaway E., Yano L., and Herzig K. The effect of d-amphetamine, clonidine, and yohimbine on human information processing. Psychophysiology 31 (1994) 331-337
11. Hamburger H.L., and vd Burgt M.A. Global field power measurement versus classical method in the determination of the latency of evoked potential components. Brain Topogr 3 (1991) 391-396
12. Heukrodt C., Powazek M., Brown W.S., Kennelly D., Imbus C., Robinson H., et al. Electrophysiological signs of neurocognitive deficits in long-term leukemia survivors. J Pediatr Psychol 13 (1988) 223-236
13. Inagaki M., Yoshikawa E., Matsuoka Y., Sugawara Y., Nakano T., Akechi T., et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 109 (2007) 146-156
14. Keppel G. Design and analysis: a researchers handbook. 3rd ed. (1991), Prentice Hall, Englewood Cliffs, NJ
15. Kok A. Event-related-potential (ERP) reflections of mental resources: a review and synthesis. Biol Psychol 45 (1997) 19-56
16. Kok A. Age-related changes in involuntary and voluntary attention as reflected in components of the event-related potential (ERP). Biol Psychol 54 (2000) 107-143
17. Kreukels B.P.C., Schagen S.B., Ridderinkhof K.R., Boogerd W., Hamburger H.L., and Dam F.S. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 94 (2005) 53-61
18. Kreukels B.P., Schagen S.B., Ridderinkhof K.R., Boogerd W., Hamburger H.L., Muller M.J., et al. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study. Clin Breast Cancer 7 (2006) 67-78
19. Lee G.D., Longo D.L., Wang Y., Rifkind J.M., Abdul-Raman L., Mamczarz J.A., et al. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin Cancer Res 12 (2006) 198-205
20. Lehmann D., and Skrandies W. Reference-free identification of components of checkerboard-evoked multichannel potential fields. Electroencephalogr Clin Neurophysiol 48 (1980) 609-621
21. Macleod J.E., Deleo J.A., Hickey W.F., and Ahles T.A. Cancer chemotherapy impairs contextual but not cue-specific fear memory. Behav Brain Res 181 1 (2007) 168-172
22. Morault P.M., Bourgeois M., Laville J., Bensch C., and Paty J. Psychophysiological and clinical value of event-related potentials in obsessive-compulsive disorder. Biol Psychiatry 42 (1997) 46-56
23. Oades R.D., Dittmann-Balcar A., Schepker R., Eggers C., and Zerbin D. Auditory event-related potentials (ERPs) and mismatch negativity (MMN) in healthy children and those with attention-deficit or tourette/tic symptoms. Biol Psychol 43 (1996) 163-185
24. Pfefferbaum A., Roth W.T., and Ford J.M. Event-related potentials in the study of psychiatric disorders. Arch Gen Psychiatry 52 (1995) 559-563
25. Rodenhuis S., Bontenbal M., Beex L.V., Wagstaff J., Richel D.J., Nooij M.A., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. New Engl J Med 349 (2003) 7-16
26. Reiriz A.B., Reolon G.K., Preissler T., Rosado J.O., Henriques J.A., Roesler R., et al. Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamide in mice. Clin Cancer Res 12 (2006) 5000-5001
27. Saito H., Yamazaki H., Matsuoka H., Matsumoto K., Numachi Y., Yoshida S., et al. Visual event-related potential in mild dementia of the Alzheimer's type. Psychiatry Clin Neurosci 55 (2001) 365-371
28. Schagen S.B., Hamburger H.L., Muller M.J., Boogerd W., and Van Dam F.S. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol 51 (2001) 159-165
29. Schagen S.B., Muller M.J., Boogerd W., Mellenbergh G.J., and van Dam F.S. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 98 (2006) 1742-1745
30. Schagen S.B., Van Dam F.S., Muller M.J., Boogerd W., Lindeboom J., and Bruning P.F. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85 (1999) 640-650
31. Seigers R., Schagen S.B., Beerling W., Boogerd W., van Tellingen O., van Dam F.S., et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res 186 (2008) 168-175 Epub ahead of print
32. Semlitsch H., Anderer P., Schuster P., and Presslich O. A solution for reliable and valid reduction of ocular artifacts, applied to the P300 ERP. Psychophysiology 23 (1986) 695-703
33. Silverman D.H., Dy C.J., Castellon S.A., Lai J., Pio B.S., Abraham L., Waddell K., Peterson L., Phelps M.E., and Ganz P.A. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 103 3 (2007) 303-311
34. Van Dam F.S., Schagen S.B., Muller M.J., Boogerd W., vd Wall E., Droogleever Fortuyn M.E., et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90 (1998) 210-218
35. Van der Molen M.W., Bashore T.R., Halliday R., and Callaway E. Chronopsychophysiology: mental chronometry augmented by psychophysiological time markers. In: Jennings J.R., and Coles M.G.H. (Eds). Handbook of cognitive psychophysiology: central and autonomic nervous system approaches (1991), John Wiley & Sons Ltd 9-178
36. Van der Stelt O., Frye J., Lieberman J.A., and Belger A. Impaired P3 generation reflects high-level and progressive neurocognitive dysfunction in schizophrenia. Arch Gen Psychiatry 61 (2004) 237-248
37. Wefel J.S., Lenzi R., Theriault R.L., Davis R.N., and Meyers C.A. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100 (2004) 2292-2299
38. Winocur G., Vardy J., Binns M.A., Kerr L., and Tannock I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav 85 (2006) 66-75